| CORVUS PHARMAC. DL-,0001 |
| USA |
| Gesundheit |
| US2210151005 / A2AFXS |
| C17 (Frankfurt) / CRVS (NASDAQ) |
| FRA:C17, ETR:C17, C17:GR, NASDAQ:CRVS |
| - |
| https://www.corvuspharma... |
|
Corvus Pharmaceuticals Inc. is a clinical-stage bi..
>Volltext.. |
| 459.74 Mio. EUR |
| 404.59 Mio. EUR |
| - |
| -33.42 Mio. EUR |
| -13 Mio. EUR |
| -0.17 EUR |
| 0.87 Mio. EUR |
| 2.47 Mio. EUR |
| -27.65 Mio. EUR |
| 8.14 |
| - |
| 74.83% |
| - |
| - |
| - |
| - |
| CORVUS PHARMA, CORVUS PHARMACEUTICALS, CORVUS PHARMACEUTICAL |
| 20.01.26 |
|
||||
|